Fate Therapeutics INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
Redmile Group, LLC has completed an internal reorganization of its holdings in Fate Therapeutics, shifting assets to specialized subsidiaries while maintaining a 14.9% aggregate stake.
NASDAQ
Redmile Group, LLC, a key investor in Fate Therapeutics Inc., has elected to increase its maximum beneficial ownership percentage of pre-funded warrants from 9.99% to 14.99%, effective 61 days after July 1, 2025.